Biodexa Pharmaceuticals (BDRX) Net Margin (2015 - 2020)

Biodexa Pharmaceuticals has disclosed Net Margin across 6 years of filings, most recently posting 13163.1% for Q4 2020.

• In Q4 2020, Net Margin fell 1093190.0% year-over-year to 13163.1%; the TTM figure through Dec 2020 stood at 1388.47% (down 110973.0% YoY), while the FY2023 annual figure was 1856.69%, down 76199.0% from the prior year.
• Net Margin came in at 13163.1% for Q4 2020 at Biodexa Pharmaceuticals, down from 10369.05% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 165.76% in Q4 2017 to a low of 13163.1% in Q4 2020.
• Average Net Margin over 5 years is 4416.1%, with a median of 1309.18% recorded in 2018.
• Year-over-year, Net Margin jumped 11089 bps in 2016 and plunged 1093190 bps in 2020.
• Over 5 years, Net Margin stood at 180.34% in 2016, then gained by 8 bps to 165.76% in 2017, then sank by 134 bps to 387.17% in 2018, then sank by 476 bps to 2231.19% in 2019, then slumped by 490 bps to 13163.1% in 2020.
• Per Business Quant data, the three most recent Net Margin figures were 13163.1% in Q4 2020, 10369.05% in Q3 2020, and 2231.19% in Q4 2019.